Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
[Box: see text].
Immunotherapy. 2024 Aug 19 [Epub ahead of print]
Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy., Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, 16132, Italy., Medical Oncology Unit, Ospedale San Paolo, Savona, 17100, Italy., Department of Medical Oncology, Università Campus Biomedico of Roma, Rome, 00128, Italy., Department of Urology & Gynecology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Napoli, 80131, Italy., Medical Oncology Department, Ospedale Santa Chiara - APSS, Trento, 38122, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, 10128, Italy., Oncology Unit, Villa Scassi Hospital, Genova, 16149, Italy., Department of Health Sciences, Section of Clinical Pharmacology & Oncology, University of Firenze, Firenze, 50139, Italy., Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno-Azienda Sanitaria Locale CN2, Verduno, 12060, Italy., Medical Oncology, St. Salvatore Hospital, L'Aquila, 67100, Italy., SSD Oncologia Medica, Ospedale Sirai di Carbonia, ASL Sulcis, 09013, Italy., Medical Oncology, Ospedale Civico (A.R.N.A.S.), Palermo, 90127, Italy., Oncology department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013, Italy., Department of Oncology & Advances Technologies, IRCCS - AUSL Reggio Emilia, Guastalla, 41016, Italy., Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milan, 20141, Italy., Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, NE7 7DN, United Kingdom., Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, United Kingdom., Medical Oncology Unit, University Hospital of Parma, Parma, 43126, Italy.